Intellia Therapeutics, Inc. (NTLA) incurred second-quarter 2024 loss of $1.31 per share (excluding a one-time expense of change in fair value of investments), which was wider than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago quarter, Intellia had incurred a loss of $1.40 per share. Including the above one-time expense, the company reported a loss of $1.52 per share in the second quarter of 2024. The company's total revenues currently comprise only collaboration revenues. NTLA reported re ...